WuXi Vaccines Launches Its First Vaccines CDMO Site in China
WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO site in Suzhou, China. The opening will add drug substance and drug product capacity, with end-to-end…
Syngene to acquire multi-modal facility from Stelis Biopharma Ltd, adding 20,000 liters of installed biologics drug substance manufacturing capacity, with scope for further expansion, and a high speed, commercial scale, fill-finish unit
Syngene today announced the acquisition of Unit 3 biologics manufacturing facility in Bangalore, India, from Stelis Biopharma Limited (SBL). The companies have entered into a binding term sheet and, on completion of the transaction, the site will add 20,000 liters…
